These data suggest that GalC-competent, donor-derived macrophages may provide some benefit in peripheral nerves through immunomodulatory mechanisms (Reddy et al., 2011; Karumuthil-Melethil and Gray, 2016; Potter and Petryniak, 2016; Weinstock et al., 2020), but are unable to correct the metabolic defect in Schwann cells leading to progressive PNS disease in transplant recipients. The gene discussed is GALC; the disease is peripheral nervous system disorder.